Deals Shaping The Medical Industry, June 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
The Federal Trade Commission is leveraging other statutory authorities under the FTC Act and working with state regulators to garner monetary relief for consumers in the year since a Supreme Court decision shut down the commission’s longtime pathway for doing so under Sec. 13(b). FTC Bureau of Consumer Protection director Samuel Levine provided an update – and a warning to industry – at the NAD 2022 conference.
The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.